Dexcom stock price dexcom’s $125 stock price today signals

Dexcom’s $125 stock price today signals steady demand as the firm remains a top healthcare growth pick among investment banks, reinforced by consistent earnings surprises. On September 18, 2025, Hunterbrook Media ("Hunterbrook") published a short report entitled "Dexcom's Fatal Flaws".  The Hunterbrook report alleged , among other things, that Dexcom "made an unauthorized design change to a key component of the G7", the Company's continuous glucose monitoring system for diabetes management, and that "G7 users have been hospitalized and died" following inaccurate glucose readings from G7 devices. On the product front, DexCom is leveraging both hardware and software to to keep its business afloat amid rising competition. The upcoming 15-day G7 sensor, cleared by the FDA, is set to be launched in the second half of 2025, while development on the next-gen G8 platform is underway, promising smaller, multi-analyte-ready wearables. Meanwhile, over 400,000 downloads of DexCom’s new Stelo biosensor app highlight consumer adoption beyond diabetes, with integrations like Oura Ring enabling a more personalized health ecosystem. Dexcom stock price hovered at $122.90 in mid-day trading, supported by increasing institutional accumulation. Technical indicators such as the 50-day SMA crossing above the 200-day SMA suggest bullish momentum in the near-to-mid term.